A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood

Healthy Clinical Trial

Official title:

The Effect of Multiple Doses of BI 425809 on the Pharmacokinetics of Multiple Doses of a Combination of Ethinylestradiol and Levonorgestrel Following Oral Administration in Healthy Premenopausal Female Subjects (an Open-label, Two-period, Fixed Sequence Design Trial With run-in Period)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05613777
• Other study ID #: 1346-0036
• Secondary ID: 2022-500050-42-0
• Status: Completed
• Phase: Phase 1
• Start date: November 24, 2022
• Est. completion date: October 4, 2023

Study information

• Verified date: October 2023
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of this trial is to investigate the possible effect of multiple oral doses of BI 425809 on the steady state pharmacokinetics of ethinylestradiol (EE) and levonogestrel (LNG) (administered as the combined oral contraceptive Microgynon®).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: October 4, 2023
• Est. primary completion date: October 4, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Healthy premenopausal female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (Blood pressure(BP), Pulse rate (PR)), 12-lead Electrocardiogram (12-lead ECG), and clinical laboratory tests without any clinically significant abnormalities.
• Age of 18 to 35 years (inclusive).
• Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive).
• Signed and dated written informed consent in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
• Female subjects who meet any of the following criteria starting from at least 30 days

before the first administration of BI 425809 and until 30 days after trial completion:

• Use of adequate contraception, e.g. non-hormonal intrauterine device plus condom.
• Sexually abstinent.
• A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment).
• Surgically sterilised (including hysterectomy). Exclusion Criteria: Subjects will not be allowed to participate, if any of the following general criteria

apply:

• Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator.
• Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre(s) of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 beats per minute (bpm).
• Any laboratory value outside the reference range that the investigator considers to be of clinical relevance.
• Any evidence of a concomitant disease assessed as clinically relevant by the investigator.
• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
• Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair).
• Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders.
• History of relevant orthostatic hypotension, fainting spells, or blackouts. Further exclusion criteria apply.

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Microgynon®
ethinylestradiol (EE) and levonorgestrel (LNG)
• BI 425809
BI 425809

Locations

Country	Name	City	State
Germany	CRS Clinical Research Services Mannheim GmbH	Mannheim

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t (AUCt,ss )		Up to 22 days
Primary	Maximum measured concentration of the analyte in plasma at steady state over (Cmax,ss)		Up to 22 days
Primary	Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t(Cmin,ss)		Up to 22 days

External Links

•   Related Info